Streetbeat News

Products Services

PBLA

Panbela Therapeutics, Inc. (NASDAQ:PBLA) has announced the issuance of a new patent in Chile for its product Flynpovi, a fixed dose formulation of eflornithine and sulindac developed in collaboration with Sanofi. The patent, which is valid until 2036, has also been issued in the US, Australia, Mexico, and Taiwan. Flynpovi is Panbela's lead investigational product for the treatment of Familial Adenomatous Polyposis (FAP).

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 12:16 pm

CING

Cingulate Therapeutics has announced the presentation of full trial results from its Phase 3 adult efficacy and safety trial of CTx-1301 for ADHD at Psych Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 12:13 pm

CVKD

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is developing tecarfarin, a novel Vitamin K Antagonist, to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain rare medical conditions. The company believes tecarfarin is the solution for an unmet need, as recent data from the European Society of Cardiology Congress revealed more bleeding complications when switching from VKA treatment to direct oral anticoagulants in frail older patients. Cadrenal's tecarfarin has orphan drug and Fast Track designations for the prevention of systemic thromboembolism in patients with ESKD and AFib, presenting a U.S. market opportunity in excess of $2 billion per year.

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 12:12 pm

MRK

PRTG

Portage Biotech has announced a trial collaboration with Merck to evaluate Portage's adenosine antagonists in combination with Merck's Keytruda for solid tumors.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 12:10 pm

MRK

PRTG

Portage Biotech Inc. (NASDAQ:PRTG) has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate Portage's next-generation adenosine antagonists in combination with KEYTRUDA, Merck's anti-PD-1 therapy, for patients with solid tumors. The collaboration will explore Portage's adenosine 2A receptor (A2AR) antagonist, PORT-6, its adenosine 2B receptor (A2BR) antagonist, PORT-7, individually and together in combination with KEYTRUDA in various cancers.

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 12:08 pm

BIOR

Biora Therapeutics has announced that it has achieved its device performance targets for its BioJet platform. The platform uses an ingestible device to achieve systemic uptake through liquid jet delivery to the small intestine.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 12:08 pm

V

Visa (NYSE:V) is expanding its stablecoin settlement capabilities to the Solana blockchain and is working with merchant acquirers Worldpay and Nuvei. The company has already moved millions of USDC between its partners over the Solana and Ethereum blockchain networks to settle fiat-denominated payments. This move is expected to improve the speed of cross-border settlement and provide a modern option for clients to send or receive funds. Visa's work with Worldpay and Nuvei represents a significant stride in embracing the innovative potential of digital currencies.

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 12:07 pm

GH

Guardant Health has received regulatory approval in Japan for its Guardant360 CDx as a companion diagnostic to ENHERTU for the treatment of non-small cell lung cancer patients with HER2 mutations.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 12:07 pm

FAMI

Farmmi, Inc. (NASDAQ:FAMI), a Chinese agriculture products supplier, announced that one of its new customers shipped a high-volume order of dried Shiitake mushrooms to Chile. The company aims to expand its presence in emerging markets and leverage its customers' local sales and distribution networks.

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 12:06 pm

ICCM

IceCure Medical Ltd. (NASDAQ:ICCM) has received regulatory approval from the Brazilian Health Regulatory Agency for its ProSense Cryoablation System. The company expects $6.6 million in sales in the Brazilian market over the next five years. The ProSense system is a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal. The approval is expected to translate into near-term revenues due to strong demand in Brazil, which has an urgent need for minimally invasive cancer treatments.

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 12:06 pm